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Abstract— Helicobacter pylori (H. pylori) is a Gram-negative 
pathogen bacterium affecting the mucosa of the stomach and 
causing severe gastric diseases. H. pylori related infections are 
currently treated with pharmacological therapies, which are 
associated with increasing antibiotic resistance and consequent 
reduction of the efficacy down to 70-85%. Moreover, drugs have 
generally side effects that further affect the healthcare system in 
terms of additional financial and medical efforts. The aim of this 
work is to present an innovative device for the treatment of H. 
pylori infection, consisting of an ingestible lighting capsule 
performing photodynamic therapy by means of light at specific 
wavelengths. The proposed treatment is minimally invasive and 
the described system can be considered the first photodynamic 
swallowable device ever proposed. Preliminary experiments 
demonstrated that the capsule integrated with LED sources can 
provide the required lighting power to kill the bacterium with an 
efficiency up to about 96%. 
 
Index Terms— Helicobacter pylori, antibiotic resistance, 
therapeutic capsule, swallowable device, photodynamic therapy, 
LED  
I. INTRODUCTION 
ELICOBACTER pylori (H. pylori) is a Gram-negative 
microaerophilic bacterium that colonizes the mucus layer 
of the stomach and duodenum [1]. The prevalence of the 
infection is more than the 50% of the world population, up to 
90% in developing countries. 
H. pylori can cause several diseases like as chronic gastritis, 
gastric and duodenal ulcers, gastric lymphoma, 
adenocarcinoma, and extragastric disorders such as idiopathic 
thrombocytopenic purpura, iron deficiency anemia and 
vitamin B12 deficiency. H. pylori is also considered as a class 
1 carcinogen agent by the World Health Organization. 
Currently, H. pylori infection  is treated  with a pharmacologic 
therapy consisting in a combination of a proton pump inhibitor 
with two or three antibiotics showing high failure rates: due to 
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several side effects and antibiotic resistance, the efficacy of 
the pharmacologic therapy is reduced to 70-85% [1][3]. 
In order to overcome these limitations, the photodynamic 
therapy (PDT) approach has been explored worldwide for the 
treatment of this pathology. PDT was introduced at the 
beginning of the last century and originally used for tumor 
treatment. In traditional PDT, an external non-toxic dye, called 
photosensitizer, is injected or topically applied to the patient, 
being selectively accumulated in the target (i.e. a malignant 
tissue, a bacterium). After about 48-72 hours, the target is 
exposed to visible light. The interaction between the 
photosensitizer and the light, in the presence of oxygen, causes 
oxygen reactive species to be produced, thus inducing cell 
death [4]. PDT applications to kill pathogenic microorganisms 
are encountering the growing attention of clinicians, so that it 
has been proposed as a therapy for a large variety of localized 
infections. This revival of interest has largely been driven by 
the inexorable increase in drug resistance amongst many 
classes of pathogens. One of these bacteria, i.e. H. pylori, is 
known to be photo-labile without the exogenous assumption 
of photosensitizers [5]. H. pylori, in fact,  naturally owns 
photoactive porphyrins, coproporphyrin and protoporphyrin 
IX, that are natural photosensitizers. Thus, H. pylori can be 
killed by exciting them with appropriate wavelengths, for 
example by means of a traditional gastroscope opportunely 
modified with optical fibers for light delivery [6] or a light-
emitting inflatable balloon [7]. It is to be considered that all 
these solutions relied on the natural presence of oxygen in the 
treated areas and were associated with a good outcome in 
terms of killing efficacy [8]. However, these solutions have 
clear disadvantages, related to poor patient compliance due to 
their invasivity, to the high number of gastroscopic procedures 
to undergo, pain and risks of gastric perforation. To overcome 
these issues, wireless capsule endoscopy has been proposed in 
recent years [9], mainly as a diagnostic solution. Wireless 
capsule endoscopy is a non-invasive diagnostic method that 
reduces the level of discomfort and can be well tolerated by 
patients, with very few contraindications [10]. Although this 
technique was originally developed for the screening of the 
small bowel, it has been later applied to other gastrointestinal 
(GI) districts, such as the colon [11][12], esophagus and 
stomach [13][14][15]. One example of non-drug based 
therapeutic device has been proposed, with applications for the 
colon [16]. None of these devices can be applied to the 
therapy of H. pylori.  
In this paper, the design and preliminary validation of a 
wireless ingestible capsule is presented as the first PDT 
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swallowable device ever proposed. The design of the capsule 
and preliminary results are presented. 
II. MATERIALS AND METHOD 
From a technical viewpoint, it is essential to focus on the 
light emission module during the preliminary development 
phase before proceeding to the integration of the final device. 
In particular, the light emission module has to be dimensioned 
considering the required light intensity necessary to kill the 
bacterium. Afterwards, the module has been tested in vitro on 
the bacterium. Finally, the integration of the whole capsule has 
been performed, considering the efficiency of the battery with 
respect to the required performance in terms of capsule 
lifetime. 
A. Light emission module 
In order to design an efficient and reliable emission module, 
i.e. the light emitters to incorporate into the capsule, the source 
parameters have been evaluated in terms of minimal energy 
required to perform an effective therapeutic action. As a first 
step, we focussed on in vitro irradiation conditions only. One 
of the most important parameters to analyse is the irradiance E 
(W/cm
2
), corresponding to the light energy received by a 
surface (in our case: the H. pylori cultured area) per unit time 
and surface. In photobiology and photophysics, the integral of 
irradiance over the treatment time is often referred to as 
“energy dose” or simply “dose” (D), and depends on the 
radiant flux Φwatt (W) of the considered source, on the 
irradiated surface S and irradiation time T by the formula: 







                    (1) 
 
In literature [5] it has been demonstrated that the most 
effective wavelength range to kill the bacterium in vitro is 
375-425 nm (blue), with an irradiation density of 9-16 J/cm
2
 




 respectively). In the range 
625-675 nm (red), the same value of 16 J/cm
2  
is accompanied 
by a H. pylori reduction factor of about 20. 
 
 
Figure 1 Typical porphyrine absorption spectrum (adapted from [18]) 
 
These dose values correspond to about 5-8.9 mW/cm
2
 
released in 30 minutes for red and blue respectively [5], being 
30 minutes the typical gastric emptying time corresponding to 
the mean capsule permanence in the stomach.  
 
Figure 2. Penetration depth vs wavelength in human mucosa tissue (adapted 
from [19]). Red and blue wavelengths to which H. pylori is more sensitive are 
indicated by asterisks (405 and 625nm respectively). 
 
These results reflect the structure of the typical absorption 
spectrum of the natural photosensitizers of H. pylori (Fig. 1), 
and must be coupled with the knowledge of the different light 
absorption by tissues. In fact, in view of ex-vivo and in-vivo 
experiments, the optical properties of the stomach wall may 
determine a shift in the best irradiation wavelengths. In 
particular, it is worth noting that red wavelengths are more 
penetrating in the human mucosa layer respect to blue ones, 
even if these last ones are more effectively absorbed by the 
photosensitizer. Embedding red and blue LED sources in the 
same devices will then improve the overall efficacy against H. 
pylori, considering that the bacterium is mainly located under 
a mucosal layer.  
For all these reasons, low current LEDs at different 
wavelengths () have been used, with nominal peaks at 375 
and 460 nm (Nichia corp., Japan), 405 and 625 nm (Vishay 
Intertechnology, United States). In all cases, spectrum are 
broader than the nominal ones and cover the effective 
wavelenghts for killing H. pylori. 
III. EXPERIMENTAL TESTS 
A. On bench experiments 
In order to establish a proper timing for in vitro H.pylori 
irradiation necessary for eradication, LED emission spectrum, 
radiant flux and irradiance have been measured. The emission 
spectrum was acquired by a portable spectrometer (Avantes, 
The Netherlands). The radiant flux Φwatt of the single chosen 
LED, i.e. the emitted power over the whole emission solid 
angle, has been evaluated by means of an integrating sphere 
(3A-IS-V1, Ophir, United States). The integrating  sphere is a 
black body model which integrates the light emitted by the 
LED in all directions onto an embedded photodiode. Each 
LED has been powered with a battery (3.7 V, 30 mAh). The 
experimental setup for the measurement of the radiant flux is 
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shown in Fig. 3. LEDs are placed on the integrating sphere to 
measure the emission on the photodiode. 
 
Fig. 3. Experimental setup for the measurement of the radiant flux. Left: 
integrating sphere where the LED is placed for testing. Right: power meter. 
 
Each measurement has been repeated three times per LED, 
in order to improve statistical significance. The results of these 
measurements are reported in Table I and compared with the 
radiant flux calculated from the LED datasheets. For both 625 
and 460 nm LEDs, these indicated the LED luminous intensity 
Iv (cd) as a mean typical value over all emission directions. 
Starting from Iv, the luminous flux Φv in lumen has been 
calculated by the formula: 
 
 vv I2      (2) 
considering a total emission solid angle of 2 and a linear 
behaviour of Iv(). Then, the radiant flux Φwatt has been 






                                 (3) 
where V() is the luminous efficiency function (photopic 
vision). For our verification purposes, we limited calculations 
to a very simple model, neglecting the LED spectral FWHM 
(Full Width at Half Maximum) and calculating V() in 
correspondence to the respective measured emission peak 













radiant flux  
(mW) 
Calculated  
radiant flux  
(mW) 
632 625 7.4±0.1 16 
460 460 5.0±0.8 7.35 
402 405 3.25±0.26 6.8* 
379 375 6.86±1.6 9.9* 
* information given directly in the LED datasheet as typical value 
 
It is worth noting that there are discrepancies between 
theoretical and measured values. We have to consider that 
datasheet report typical emission values for Iv, whose 
variability may well be up to more than 50%. In addition, a 
more accurate calculation would need to account for the 
spectral width of the LED emission (typical FWHM is 15-25 
nm) to obtain the radiant flux by modifying eq. 3, which is 
beyond the scope of this article. For all these reasons, we 
relied on our measured values rather than on datasheet ones. 
By considering the LED datasheet, where Iv/Ivmax is plotted vs. 
α (data not shown, see Fig. 4 for α), we derived the behaviour 
of Iv/Ivmax vs. the solid angle for light emission  by 
considering its definition: =2π (1-cos α), finding a very good 











1maxvv II     (4) 
 
with 0    2, being  = 0 the null solid angle 
corresponding to the forward LED axis direction (α=0). 
Correspondingly, the luminous flux Iv() is derived by 
integrating over , obtaining Iv()  
2
. For a 
monochromatic source and thanks to eq. 3, it follows that the 
radiant flux is:  
  2 kwatt      (5) 
where k is an unknown constant depending on the maximum 
value for v(). For our purposes, we can model the single 
LED irradiation by Fig. 4, where d is the distance between the 
LED and the illuminated surface, A is the irradiated circular 
area of radius r due to emission within the solid angle  and 
the LED emission is concentrated in its center point. We 
define A90% as the “effective irradiated area” where 90% of the 
total radiant flux is delivered. This choice defines the value for 
=90%. Correspondingly we find 90% by applying the 
definition of : 90% = arccos(1/10). In turn, this defines 
A90% as (see also Fig. 4): 
   22%90%90 9 dtgdA       (6) 
 
It is worth noting that 90%, and consequently A90% do not 
depend on k (eq. 5), which means we do not need to know the 
maximum LED luminous intensity (often unknown) to define 
them. In this way we can associate an illuminated area to each 
LED. This determines an error of about 10%, which seems 
acceptable for our modeling purposes. 
 




Figure 4  Irradiated area A at distance d for each LED. 
 
For in vitro irradiation, a dedicated Delrin® support has 
been fabricated, as shown in Fig. 5. Afterwards, a single LED 
has been embedded in a 2 mm transparent resin and positioned 
directly onto the photodiode.  
 
   
Fig. 5. Dedicated LED support for in vitro irradiation (left) of  H.pylori 
cultures (right). 
 
Measurement of irradiance uniformity at a 2 cm distance 
(data not shown) for a single LED in a fixed LED position has 
given a value of about 15%, defined as maximum deviation 
from mean value over the Petri dish surface. During in vitro 
irradiation, light diffusion due to the Delrin® support 
occurred, so that almost all the radiant flux was impinging on 
the Petri dish surface (data not shown). 
 
B. In vitro experiments  
H.pylori laboratory-adapted strain (ATCC 49503) was 
routinely grown in liquid medium consisting of Brucella broth 
at 37°C in a microaerophilic atmosphere. After 96 hours it was 
streaked on Blood Agar plates until colonies were easily 
countable. 
Experiments have been performed to assess the killing 
efficacy of the chosen LEDs at the different wavelengths. 
After growing on agar plates, an aliquot corresponding to a 
bacterial concentration of 800000 Colony Forming Units/ml 
(CFU/ml) was used and in vitro light bacterial irradiation was 
performed on phosphate-buffered saline (PBS) in Petri dishes. 
During light delivery, dishes with H.pylori in liquid medium 
were maintained in plastic bags at 37°C in microaerophilic 
atmosphere and sterile conditions. For this reason, the 
experimental setup of Fig. 5 (LED in a fixed position) has 
been equipped with a magnetic reed switch allowing to turn 
the LED modules on and off in an easy way without opening 
the envelop. The final configuration of the experiment is 
shown in Fig. 6. Irradiation time was 30 minutes for all 
samples, separately with red (625 nm) and blue (405 nm) 
light. These LED modules correspond to those integrated in 
the capsule, as described in Section IV. During irradiation, 
envelops with cultured bacteria were kept at 37°C inside a cell 
incubator in microaerophilic atmosphere and sterile 
conditions. A control sample (no irradiation) was subject to 




Fig. 6. Transparent envelop with inside  the dedicated irradiation LED support 
and the H. pylori cultures (idle). 
 
Then, survival fraction determination was performed. 
Following light irradiation, a suspension aliquot was removed 
from each Petri dish, subjected to serial tenfold dilutions and 
plated at 37°C in microaerophilic conditions on Blood Agar 
for 4 days. Surviving CFU were counted and recorded for 
analysis and survival fractions were determined relative to 
unilluminated bacterial suspensions. Irradiation results are 
shown in Table II. 
 
TABLE II 








CFU reduction after 
irradiation  
(%) 
625 40000 95 
460 30000 96.25 
405 30000 96.25 
375 50000 84 
 
IV. SYSTEM INTEGRATION 
After proving the in vitro efficacy of the LEDs, the 
ingestible capsule device has been designed in order to 
integrate all the needed components and considering 
dimensions that allow an easy swallowability (i.e. the target 
dimensions are the ones of commercial capsules: diameter 11-
14 mm; length 26-30 mm). In order to prevent capsule 
retention, the clinical protocol foresees since now the use of a 
dissolvable (dummy) capsule to verify the functional patency 
of the small bowel and consequently identify those patients 
who can safely undergo a capsule therapy [20]. Two capsule 
types have been designed and built: a research capsule, a 
prototype including the LEDs and a more performant battery 
that is still not acceptable for clinical use, and a pre-industrial 
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prototype, including components that are certified or 
certifiable for clinical use. Both types have been equipped 
with 8 LEDs positioned on an electronic board including a 
magnetic switch (Memscap, USA) and a battery. The 
magnetic switch is normally in a closed reed state and is used 
to switch on the capsule power by removing the device from a 
magnetized external case when in use.  
The research prototype has been built in two different 
versions, one emitting red light only (625nm) and the other 
emitting blue light only (405nm). The light sources correspond 
to the above-described LED modules (405 and 625nm). Each 
prototype has a polymeric shell 27 mm in length and 14 mm in 
diameter. Two symmetric transparent windows are integrated 
in the lateral area of the capsule for enabling illumination from 
the internal light sources. The LEDs are positioned on a PCB 
having dimensions of 13 mm x 16 mm x 2 mm, designed and 
dimensioned for embedding the LEDs and the electronic 
components. The 3D sketches of both research and pre-
industrial prototypes with main components are shown in Figs. 
7 and 8. A LiPo (Lithium-Polymer) battery (3.7 V, 30 mAh, 
Plantraco, Canada) has been used for the research prototype. 
Although this battery has high energy density (200 Wh/kg) 
and a convenient form factor (13 mm x 17 mm x 5.7 mm), still 
it is non-certified for clinical use. However, it is commonly 
used for capsule research devices and miniaturized robots as 
main power source [14][15][17]. 
 
 
Fig. 7. Research prototype (14 mm diameter, 27 mm length); 3D sketch (Left) 






Fig. 8. Pre-industrial prototype 3D sketch (12 mm diameter, 27 mm length). 
 
The pre-industrial prototype has been built in one version 
only emitting red light at 625nm; it has a transparent 
polycarbonate shell having dimensions of 27 mm length and 
12 mm diameter. The capsule has been equipped with 8 LEDs 
positioned with radial symmetry, in order to maximise the 
total irradiated area and for adapting the internal geometry to 
the battery shape factor. The LEDs are positioned on a LED 
support having dimensions of 6 mm x 6 mm x 4.5 mm 
embedding both LEDs and electronic components. The power 
source consists in a 2L76 3-Volt Lithium cylindrical battery 
(160 mAh, 11.6 mm diameter, 10.6 mm height). A reed switch 
has been included as well in analogy with the research 
prototype. The used battery is certifiable for clinical use, being 
a traditional Lithium-Ion battery commonly used in implanted 
medical devices (i.e.  pacemakers). 
A comprehensive model of the light power per unit surface 
impinging on the various regions of the stomach (and stomach 
antrum in particular) due to capsule irradiation is beyond the 
scope of this article. Nevertheless, for both prototypes we 
present two exemplary cases, corresponding to a “short” 
(2mm) and “long” (15mm) mean distance (d, see eq. 6) 
between the capsule and the stomach wall  in the collapsed 
and extended stomach conditions respectively. This very 
simple model considers the capsule ideally positioned along 
the symmetry axis of the antrum region, whose dimensions in 
the distended state are compatible with a total surface area of 
the order of 50 cm
2
 and lateral dimensions up to more than 
4cm. The mean time for therapy was estimated to be about 30 
minutes, corresponding to the mean gastric emptying time. 
The energy dose released from each capsule prototype has 
been calculated by using the measured radiant flux and 
capsule geometry, considering the presence and positioning of 
8 LEDs for each prototype represented in Fig. 7 and 8. In the 
pre-industrial prototype, the irradiated area (eq. 6) is estimated 
to be 9 cm
2
, corresponding to eight times the spot produced 
by the single LED for the collapsed case (no significant lobe 
superposition) and >50 cm
2 
for the distended case. In the 
research prototype, LED lobe superposition (Fig. 9) defines a 
smaller irradiation area of 23.5 = 7 cm
2
 in the collapsed 
case. In the distended antrum case, eq. 6 gives a value >50 
cm
2
, like with the pre-industrial prototype, meaning that the 
whole antrum surface is illuminated. 
  
TABLE III 














TO REACH THE 
TARGET DOSE 
Pre-industrial 
collapsed 9 11.8 2 
distended 50 2.1 11 
Research 
collapsed 7 6.7 3 (2) 
distended 50 0.94 17 (10) 
Table III – Irradiation parameters for the capsule prototypes in the collapsed 
and distended stomach models (red light emission). Numbers in parenthesis 
refer to blue light emission. 
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In the cases where A90%>50cm
2
, we assume that the mean 
power per unit surface illuminating the gastric wall is equal to 
the sum of all the LED emitted power divided by 50cm
2
 (see 
also Table III). It is clear that in the collapsed stomach case, 
the target dose is reached only in the fraction of surface 
reached by the illumination. The pre-industrial red-light 
emitting prototype has a mean fluence of 12 J/cm
2
 calculated 
as 7.4 mW 81800s over 9 cm
2
. In order to reach the target 
energy dose of 16 J/cm
2
 for red light,  at least 2 or 11 capsules 
will be necessary in the collapsed and distended stomach case 
respectively. To test the performance of a different geometry 
for the capsule LED sources, we have also analyzed the case 
of an hypothetic in vivo application of the research prototype. 
This emits a mean fluence of about 6.7 or 0.94 J/cm
2
, equal to 
3.25mW·8·1800s over 7 or 50 cm
2
 (collapsed and distended 
case respectively). Considering as before the respective cases 
of collapsed and distended stomach antrum wall, this means 
that at least 3 or 17 capsules would be necessary to treat the 
gastric target area for red light (~16 J/cm
2
) and that 2 or 10 
capsules would be necessary for blue light (~9 J/cm
2
).  
Figure 9: LED lobe superposition in the research prototype. Dotted red line 
represents the total irradiated area. 
 
 




Fig. 10. Red (Left) and blue (Right) research prototypes. 
 
  
Fig. 11. Pre-industrial red prototype: idle (Left) and alight (Right). 
 
The pre-industrial prototype has been qualitatively tested on 
a distended stomach 3D model made in silicone (Fig. 12) in 
order to assess the overall light diffusion with respect to the 
capsule position. 
The proposed capsule has no special parts for distending the 
stomach naturally collapsed in the fasting state. The distended 
condition can be obtained e.g. by  making the patient drinking 
plain or sparkling water, that provide negligible light 
absorption; stomach distension reduces blind areas as well. 
Although stomach distension can help to expose the gastric 
internal surface to light, at the same time it increases the 
distance between the capsule and the irradiated tissue which is 
illuminated by a lower fluence (Tab. III), thus decreasing the 
single capsule efficiency. The need for stomach distension 
during the capsule treatment and the way it affects the overall 
efficacy will be evaluated in the future, as soon as a pilot 
clinical test in humans will be performed. In addition, bacteria 
located both on the surface and deeper in the tissue plicae can 
be targeted thanks to the red and blue light emission 
respectively. 
Additional methods for enlarging the irradiated area will be 
evaluated. Among them, the use of a light diffusing material 
for the capsule surface can be an option, even if the use of 
LEDs with a wider emission angle seems to be a more 
promising solution, together with the use of additional LED 
sources.  
 
Fig. 12. Qualitative red light diffusion in a distended stomach model. 
V. CONCLUSION 
In this paper, an ingestible capsule for the photodynamic 
treatment of H. pylori has been proposed, built and 
characterized for the first time. As a first step, we confirmed 
the feasibility of in vitro photodynamic therapy of H. pylori, 
by means of tiny LEDs powered by a battery, in a completely 
wireless approach. LEDs at 375, 405, 460, 625 nm 
wavelengths have been used and their radiant fluxes measured, 
whose values fit the requirements for H. pylori killing, taken 
from scientific literature (threshold irradiation dose: 16 J/cm
2 
for 625 nm light and 9 J/cm
2 
for 405 nm, 30 minute therapy, 
2 and 15 mm working distance). Both red and blue lights (625 
nm and 405 nm respectively) were associated with a killing 
efficiency of about 96%. On the basis of these results, the 
LEDs, a battery and dedicated electronic boards have been 
embedded into both a research and a pre-industrial capsule 
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prototype. These have been fabricated in swallowable 
dimensions (27 mm length- 14 mm diameter and 27 mm 
length - 12 mm diameter respectively). The capsule can be 
considered as the first photodynamic swallowable device ever 
proposed. We believe that our device might pave the way to a 
promising and innovative approach towards the eradication of 
H. pylori, alternative to pharmacologic therapy. Considering 
previous work that found a bacterial killing between 77% and 
99.9% [7][7][8] we are confident that our device will be 
capable to provide an effective treatment of H. pylori 
infections. It is worth noting that, as for example stated in [7], 
the presence of a single treatment session with non-wireless 
stomach illumination methods was one of the main causes of 
eradication failure, due to H. pylori re-growth in the 
subsequent days. This substantial problem is overcome by the 
easy and frequent repeatability of our wireless capsule 
approach, mainly due to its minimal invasivity. 
Further steps of experimentation will consist in animal tests 
(mini-pigs) to assess the capsule mechanical resistance, the 
overall safety within the whole gastrointestinal tract and the 
capsule permanence time in the stomach antrum in a 
preclinical model (i.e. with the presence of peristalsis), as 
indications of the overall efficacy of the capsule. The 
assessment of the capsule treatment efficacy in animals is not 
scheduled, due to substantial differences between H. pylori 
strains in animals and those in humans. For this reason, 
experimental tests on humans are being planned to assess the 
efficiency of the capsule and the minimum light dose required 
(i.e. the number of capsules). Clinical tests will also help 
understanding whether the area irradiated by the capsule is 
sufficient for eradication. In this perspective, it is encouraging 
the fact that the capsule naturally locates in the stomach 
antrum, where the highest bacterium concentration is found. 
From an economic viewpoint, we expect that the cost for 
eradication with our device  is possibly comparable with the 
one of antibiotic therapy (about 50-60 €). In a first phase our 
targets will be antibiotic resistant patients, where the search 
for innovative and effective therapeutic solutions is 
paramount. 
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